ALNYLAM PHARMACEUTICALS, INC.ALNY

Market cap

$56.9B

P/E ratio

	Dec 31, 2010	Dec 31, 2011	Dec 31, 2012	Dec 31, 2013	Dec 31, 2014	Dec 31, 2015	Dec 31, 2016	Dec 31, 2017	Dec 31, 2018	Dec 31, 2019	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Cash and cash equivalents	75	70	51	53	75	181	194	645	420	547	497	820	866	813	966
Marketable debt securities	159	76	71	193	527	848	424	1,045	663	975	1,333	1,549	1,298	1,616	1,720
Marketable equity securities	-	-	-	-	-	-	-	-	1	14	45	67	28	11	8
Accounts receivable, net	-	-	-	-	-	-	-	-	19	43	102	199	238	328	405
Inventory	-	-	-	-	-	-	-	-	24	56	75	86	129	89	79
Prepaid expenses and other current assets	-	4	3	4	10	17	22	40	74	80	63	88	133	126	117
Total current assets	254	152	125	254	746	1,105	672	1,765	1,201	1,716	2,615	2,809	2,692	2,983	3,295
Property, plant and equipment, net	18	15	20	16	22	28	115	182	321	425	465	502	523	526	503
Operating lease right-of-use assets	-	-	-	-	-	-	-	-	-	221	241	232	215	200	191
Deferred tax assets	-	-	-	-	-	-	-	-	-	-	-	-	-	-	117
Restricted investments	-	-	-	-	-	-	150	30	45	15	41	41	49	49	69
Other assets	-	-	0	-	-	1	2	4	9	18	45	60	66	72	65
Total assets	393	282	288	421	1,080	1,387	1,263	1,995	1,575	2,395	3,407	3,643	3,546	3,830	4,240
Accounts payable	9	6	4	6	15	17	54	28	60	50	52	73	98	56	88
Accrued expenses	11	12	12	14	24	29	42	72	113	197	356	395	545	713	887
Operating lease liabilities	-	-	-	-	-	-	-	-	-	28	37	41	42	42	42
Deferred revenue	-	-	-	-	-	-	-	-	3	78	127	149	42	103	55
Royalty Liability, Current	-	-	-	-	-	-	-	-	-	-	13	37	40	55	113
Total current liabilities	102	81	48	54	95	62	132	144	179	353	585	696	768	968	1,186
Operating Lease, Liability, Noncurrent	-	-	-	-	-	-	-	-	-	276	293	281	261	243	230
Deferred revenue, net of current portion	-	-	-	-	-	-	-	-	0	318	225	152	194	188	-
Convertible debt	-	-	-	-	-	-	-	-	-	-	-	-	1,017	1,021	1,025
Royalty Liability, Noncurrent	-	-	-	-	-	-	-	-	-	-	1,058	1,151	1,252	1,322	1,334
Other liabilities	0	1	-	-	-	1	3	4	5	9	38	99	213	308	398
Total liabilities	235	164	153	150	143	122	343	228	273	956	2,391	3,055	3,705	4,051	4,173
Preferred Stock, Value, Issued	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Common Stock, Value, Issued	0	0	1	1	1	1	1	1	1	1	1	1	1	-	1
Additional paid-in capital	500	519	625	846	1,843	2,506	2,610	3,948	4,175	5,201	5,644	6,058	6,455	6,811	7,388
Accumulated other comprehensive loss	1	-0	16	20	49	4	-33	-34	-33	-37	-44	-33	-45	-23	-35
Accumulated deficit	-343	-401	-507	-596	-957	-1,247	-1,657	-2,148	-2,841	-3,727	-4,585	-5,438	-6,569	-7,010	-7,288
Total stockholders’ equity (deficit)	158	118	134	270	936	1,265	920	1,766	1,302	1,439	1,016	588	-158	-221	67
Total liabilities and stockholders’ equity (deficit)	393	282	288	421	1,080	1,387	1,263	1,995	1,575	2,395	3,407	3,643	3,546	3,830	4,240